Gujarat Themis Biosyn Ltd - 506879 - Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Gujarat Themis Biosyn approved FY26 audited financial results, reporting a total income of ₹168.25 crore and a net profit of ₹46.68 crore. The company recommended a final dividend of ₹0.67 per equity share and approved a preferential issue of equity shares.
May 25 2026 15:07:09
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Ltd. will acquire MicroBiopharm Japan Co., Ltd. for Rs. 1,300 crore. This acquisition marks a strategic move to transform GTBL into a technology-driven Contract Development Manufacturing Organization (CDMO) platform. The deal will be completed by September 2026.
May 22 2026 21:18:08
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Ltd. (GTBL) will acquire 100% equity of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. This acquisition is strategic, aimed at transforming GTBL into a globally integrated CDMO platform with advanced fermentation and biotechnology capabilities.
May 22 2026 20:48:08
Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Gujarat Themis Biosyn acquired 100% equity in MicroBiopharm Japan Co., Ltd. for Rs.1,300 crore (JPY 21.5 billion). This strategic acquisition aims to transform GTBL into a technology-driven Contract Development Manufacturing Organization (CDMO) platform by enhancing its fermentation capabilities and proprietary technologies.
May 22 2026 20:43:17
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited (GTBL) has acquired 100% equity in Japan's MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. This strategic acquisition will enable GTBL to transition into a technology-driven CDMO platform, enhancing capabilities in microbial fermentation and biotechnology-based manufacturing.
May 22 2026 20:39:46
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited (GTBL) has acquired 100% equity in Japan's MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. This strategic acquisition will enable GTBL to transition into a technology-driven CDMO platform, enhancing capabilities in microbial fermentation and biotechnology-based manufacturing.
May 22 2026 20:39:46
Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Acquisition
Gujarat Themis Biosyn is acquiring 100% of MicroBiopharm Japan Co., Ltd. for approximately INR 1,300 Crores. This strategic move strengthens GTBL's CDMO capabilities in precision fermentation and biotechnology.
May 22 2026 20:37:03
Gujarat Themis Biosyn Limited
Gujarat Themis board is scheduled to meet on May 25, 2026, to discuss and approve various options for fundraising. The specific mode of raising funds will be determined during the meeting.
May 20 2026 23:22:11
Gujarat Themis Biosyn Limited
Gujarat Themis board is scheduled to meet on May 25, 2026, to discuss and approve various options for fundraising. The specific mode of raising funds will be determined during the meeting.
May 20 2026 23:16:28
Gujarat Themis Biosyn Limited
Gujarat Themis board is scheduled to meet on May 25, 2026, to discuss and approve various options for fundraising. The specific mode of raising funds will be determined during the meeting.
May 20 2026 23:16:28
Read More